



Research Letter

Facility Fees for Colonoscopy Procedures at Hospitals and Ambulatory Surgery Centers

Yang Wang, PhD; Yuchen Wang, BS; Elizabeth Plummer, PhD; Michael E. Chernew, PhD; Gerard Anderson, PhD; Ge Bai, PhD

Introduction

Variation in facility fees paid for similar health services across different sites of care has received attention. For example, Medicare pays more for services delivered in hospital outpatient departments than ambulatory surgery centers (ASCs). This has led to recommendations and proposed legislation to equalize payments for some services.¹ While Medicare-related facility fee differences are well known and Medicare and commercial plans might be concordant, less conclusive evidence exists about variations in the commercial market.² We used new Transparency in Coverage (TIC) data disclosed pursuant to recent regulations requiring health insurers to publicly disclose commercial negotiated rates for specific procedures and facilities³ to investigate site-related facility fee differences in the commercial market. We examined within-county, within-insurer commercial facility fee differences between hospitals and ASCs for colonoscopy procedures, which are shoppable, largely homogeneous, and commonly performed in both settings.⁴

Methods

This cross-sectional study followed the [STROBE](#) reporting guideline and used TIC insurer-disclosed pricing data for May 2023 compiled by Turquoise Health. We focused on in-network commercial fee-for-service facility fees disclosed by 4 major health insurers—Anthem, Inc; Cigna Group; Healthcare Service Corporation (HCSC); and UnitedHealthcare—for 3 common colonoscopy procedures (*Current Procedural Terminology [CPT] codes 45378, 45380, and 45385*). For each procedure, a facility fee was obtained for every unique combination of insurer, hospital or ASC (identified by national provider identifier), and fee type (negotiated or fee schedule). Median facility fee was used when a combination contained multiple facility fees across plans operated by the insurer. We excluded facility fees expressed as percentages and the 1% highest and lowest values for each procedure as potential data anomalies according to literature using price transparency data.⁵ Institutional review board approval was not sought per 45 CFR §46, because no human participants were involved.

For each procedure, nationwide mean commercial facility fees were compared between hospitals and ASCs using 2-sided *t* tests. To check TIC data validity, we compared the results with mean colonoscopy facility fees for hospitals and ASCs from the 2021 Merative Marketscan research database, which contains commercial claims but not insurer, facility, or county identifiers. Regression models including insurer, negotiated type, and county fixed effects estimated the difference in log-transformed facility fees between hospitals and ASCs located in the same county and contracting with the same insurer. Analysis used Stata, version 17.0. Two-sided $P < .05$ was significant.

Results

The sample included 13 287 colonoscopy commercial facility fees from 3582 hospitals and 17 052 facility fees from 3899 ASCs located in 50 states and Washington, DC. These were disclosed by

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.


Anthem (6955 [22.9%]), Cigna (7862 [25.9%]), HCSC (3606 [11.9%]), and UnitedHealthcare (11 916 [39.3%]).

Nationwide mean facility fees for hospitals (\$1530 [95% CI, \$1485-\$1576], \$1760 [95% CI, \$1706-\$1813], and \$1761 [95% CI, \$1709-\$1814]) were substantially higher than those for ASCs (\$989 [95% CI, \$970-\$1008], \$1034 [95% CI, \$1015-\$1054], and \$1030 [95% CI, \$1011-\$1049]) for CPT codes 45378, 45380, and 45385, respectively (all $P < .001$) (Figure 1). Marketscan 2021 data showed similar fees. After controlling for insurer, negotiated type, and county fixed effects, estimated facility fees in hospitals were 154% (95% CI, 149%-159%), 156% (95% CI, 151%-161%), and 161% (95% CI, 155%-166%) of those in ASCs for CPT codes 45378, 45380, and 45385, respectively (all $P < .001$) (Figure 2).

Discussion


Facility fees at hospitals were approximately 55% higher than those at ASCs in the same county and with the same insurer. Potential limitations involve use of insurers' self-disclosed pricing information, including use of nonstandard codes, reporting of prices for facilities that do not perform colonoscopies, and no utilization information.^{5,6} Results might not be generalizable to other procedures or nonmajor insurers. Due to data limitations, we did not adjust for variation on system affiliation, case mix, utilization, or quality of care across hospitals or ASCs. Nevertheless, the results suggest that a site-neutral payment policy for a largely homogeneous and shoppable service may generate savings for commercial plan sponsors and beneficiaries.

Figure 1. Nationwide Mean Commercial Colonoscopy Facility Fees in Ambulatory Surgery Centers (ASCs) vs Hospitals



For colonoscopy, the *Current Procedural Terminology* (CPT) code was 45378; for colonoscopy with biopsy, 45380; and for colonoscopy with removal of polyps, 45385. As a validity check, using the 2021 Merative Marketscan research database, we found that the national mean facility fees (unadjusted for inflation) for ASCs and hospitals were \$910 vs \$1602 for CPT code 45378, \$897 vs \$1709 for CPT code 45380, and \$900 vs \$1674 for CPT code 45385. Whiskers indicate 95% CIs.

Figure 2. Regression Estimates of Facility Fees for Commercial Colonoscopy Procedures in Hospitals Compared With Ambulatory Surgery Centers



For colonoscopy, the *Current Procedural Terminology* (CPT) code was 45378; for colonoscopy with biopsy, 45380; and for colonoscopy with removal of polyps, 45385. According to stratified models by insurer, the estimated facility fee ratios were 334%, 367%, and 362% ($P < .001$) for Anthem; 141%, 123%, and 152% ($P < .001$) for Cigna; 165%, 159%, and 160% ($P < .001$) for Healthcare Service Corporation; and 104%, 105%, and 108% ($P < .001$) for UnitedHealthcare for CPT codes 45378, 45380, and 45385, respectively. Whiskers indicate 95% CIs.

ARTICLE INFORMATION**Accepted for Publication:** September 18, 2023.**Published:** December 15, 2023. doi:[10.1001/jamahealthforum.2023.4025](https://doi.org/10.1001/jamahealthforum.2023.4025)**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](https://creativecommons.org/licenses/by/4.0/). © 2023 Wang Y et al. *JAMA Health Forum*.**Corresponding Author:** Ge Bai, PhD, Johns Hopkins Carey Business School, 100 International Dr, Baltimore, MD 21202 (gbai@jhu.edu).**Author Affiliations:** Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (Yang Wang, Yuchen Wang, Anderson, Bai); Neeley School of Business, Texas Christian University, Fort Worth (Plummer); Burnett School of Medicine, Texas Christian University, Fort Worth (Plummer); Harvard Medical School, Boston, Massachusetts (Chernew); Medicare Payment Advisory Commission, Washington, DC (Chernew); Johns Hopkins University School of Medicine, Baltimore, Maryland (Anderson); Johns Hopkins Carey Business School, Washington, DC (Bai).**Author Contributions:** Dr Yang Wang and Ms Yuchen Wang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.*Concept and design:* Yang Wang, Chernew, Anderson, Bai.*Acquisition, analysis, or interpretation of data:* All authors.*Drafting of the manuscript:* Yang Wang.*Critical review of the manuscript for important intellectual content:* All authors.*Statistical analysis:* Yang Wang, Yuchen Wang.*Obtained funding:* Anderson, Bai.*Administrative, technical, or material support:* Yang Wang, Plummer, Bai.*Supervision:* Plummer, Bai.**Conflict of Interest Disclosures:** Dr Chernew reported receiving grants from Arnold Ventures during the conduct of the study and receiving personal fees from the National Institute for Health Care Management for serving on the advisory board, receiving personal fees from MITRE and the St Louis Business Group, receiving grants from Ballad Health, serving as a health advisor for LRV, and having equity in Waymark Inc outside the submitted work. Dr Bai reported serving as an expert witness for the Washington State Attorney General's Office outside the submitted work. No other disclosures were reported.**Funding/Support:** This study was supported by Arnold Ventures and PatientRightsAdvocate.org.**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.**Data Sharing Statement:** See the [Supplement](#).**REFERENCES**

1. Medicare Payment Advisory Commission. Report to the Congress: Medicare and the health care delivery system. June 2023. Accessed July 1, 2023. https://www.medpac.gov/wp-content/uploads/2023/06/Jun23_MedPAC_Report_To_Congress_SEC.pdf
2. Carey K, Morgan JR. Payments for outpatient joint replacement surgery: a comparison of hospital outpatient departments and ambulatory surgery centers. *Health Serv Res*. 2020;55(2):218-223. doi:[10.1111/1475-6773.13262](https://doi.org/10.1111/1475-6773.13262)
3. Wang Y, Wang Y, Liu A, Anderson G, Bai G. How to analyze and improve the usability of insurer price transparency data. *Health Affairs Forefront*. May 25, 2023. doi:[10.1377/forefront.20230524.904150](https://doi.org/10.1377/forefront.20230524.904150)
4. Robinson JC, Brown TT, Whaley C. Reference pricing changes the "choice architecture" of health care for consumers. *Health Aff (Millwood)*. 2017;36(3):524-530. doi:[10.1377/hlthaff.2016.1256](https://doi.org/10.1377/hlthaff.2016.1256)
5. Wang Y, Meiselbach MK, Xu J, Bai G, Anderson G. Do insurers with greater market power negotiate consistently lower prices for hospital care? evidence from hospital price transparency data. *Med Care Res Rev*. 2023; 10775587231193475. doi:[10.1177/10775587231193475](https://doi.org/10.1177/10775587231193475)
6. Whaley C, Bai G. Health care price transparency legislation: how can Congress help employers and workers? *Health Affairs Forefront*. September 8, 2023. doi:[10.1377/forefront.20230906.594215](https://doi.org/10.1377/forefront.20230906.594215)

SUPPLEMENT**Data Sharing Statement**